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OBJECTIVE: Overactive Bladder (OAB) syndrome is deﬁned
symptomatically and is suggestive of detrusor overactivity.
Detrusor overactivity can occur due to an underlying neurolog-
ical disease (neurogenic detrusor overactivity). Early identiﬁca-
tion of neurogenic detrusor overactivity may facilitate more
effective management. The objective of our study was to explore
the likely indicators supporting a neurogenic cause for detrusor
overactivity within an OAB population, providing a clearer case
for proactive investigation of bladder problems. METHODS:
The DIN–LINK database was used to conduct a 1–year retro-
spective cohort analysis of patients across Great Britain with
OAB and neurological disease. Patients who had an OAB
symptom(s) and/or a prescription for an OAB–related therapy
during the study period (September 2003–August 2004) were
included in this analysis and constituted the OAB cohort. All the
records of those within the cohort were analysed to identify
whether the patient was diagnosed or receiving treatment for
Parkinson’s disease, stroke, multiple sclerosis or spinal cord
injury. Data was analysed by age, gender and OAB symptoms.
RESULTS: The cohort contained 13,482 OAB patients, repre-
senting a prevalence of 1.7% of the population (n = 815,054) of
whom 61% (n = 8150) were women and 43% were aged over
65. In total, 1314 (10%) patients had a neurological disease, this
increased to 16% (948 patients) in those over 65. Incontinence
was experienced by 29% (n = 384) of those with a neurological
disease but in only 18% of the complete cohort. Those with neu-
rological disease also more commonly experienced urinary fre-
quency. CONCLUSION: This study suggests that there is value
in assessing patients who present with OAB symptoms for early
signs of underlying neurological conditions. It is important to
identify neurological disease as the cause of detrusor overactiv-
ity. This will help clinicians understand the aetiological factors
behind the condition and also help in its overall management.
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OBJECTIVES: The IPSS evaluates the frequency of lower urinary
tract symptoms (LUTS). The SPI score (Symptom Problem Index)
evaluates the degree of discomfort associated with each question
on the IPSS. Our objective was to clarify the possibility of a sub-
stitution of the IPSS and SPI rating scales. METHODS: The IPSS
and SPI questionnaires were self-administered to a cohort of 907
male patients presenting a BPH recently diagnosed. The rela-
tionship between SPI and IPSS was investigated through the cor-
relation between the 2 scores and by the classiﬁcation of each
symptom according to its frequency on the one hand, and the
bothersomeness that it induces on the other. RESULTS: The
mean IPSS score was 12.6 +/- 6.4, the mean SPI score was 12.2
+/- 6.5.The correlation coefﬁcient between the IPSS and SPI
scores was 0.70; the scores from the 2 rating scales showed a
very high variability. On a 0–100% scale, where 100% repre-
sents the maximal possibility, the degree of bothersomeness
observed in the cohort ranged from 35 to 55%, the induced
bothersomeness ranged from 0 to 22.6% and the frequency of
the symptoms observed ranged from 26 to 44% depending on
the 7 symptoms. CONCLUSIONS: The two questionnaires do
not collect the same information. Considering the importance of
bothersomeness associated with lower urinary tract symptoms
for making the decision about therapy, the joint use of the IPSS
and SPI seems appropriate.
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OBJECTIVES: The International Prostatic Symptom Score
(IPSS) evaluates urinary disorders symptoms frequency associ-
ated with benign prostatic hyperplasia, but does not take into
account the bothersomeness that they induce. The Symptom
Problem Index (SPI) evaluates the degree of discomfort associ-
ated with each question on the IPSS. Our objective is to quan-
tify the degree of bothersomeness induced by each BPH
symptom. METHODS: A cohort of 907 male patients with BPH
was monitored by French General Practitioners (GP). The IPSS
and SPI questionnaires were self-administered. The IPSS and SPI
scores were evaluable for 722 patients. The relationship between
SPI and IPSS was investigated through the correlation between
the 2 scores and by the construction of quadratic curve estima-
tions for each symptom. The degree of bothersomeness that each
symptom induces was explored by the Area Under the Curve
(AUC) corresponding to an IPSS item score equal to or greater
than 2 points. RESULTS: The mean IPSS score was 12.6 +/- 6.4,
the mean SPI score was 12.2 +/- 6.5. The correlation coefﬁcient
between the IPSS and SPI scores was 0.70; the scores from the
2 rating scales showed a very high variability. Induced bother-
someness varied from 0 to 23% according to the symptom eval-
uated. Nocturia seems to be the most important symptom taking
into account the bothersomeness it caused. Despite weak urinary
stream was the most frequent symptom in this cohort, it was
only involved in 4% of induced bothersomeness. CONCLU-
SIONS: The two questionnaires do not collect the same infor-
mation. The concept of induced bothersomeness allows a more
reﬁned analysis of the extent of bothersomeness associated with
each question on the IPSS. If we accept the hypothesis that both-
ersomeness is the main parameter that leads to a treatment deci-
sion, the joint use of the IPSS and SPI seems appropriate.
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OBJECTIVE: The Overactive Bladder Treatment Satisfaction
Questionnaire (OAB-S) is a self-administered instrument assess-
ing treatment satisfaction in patients with overactive bladder.
The OAB-S has been developed for worldwide use; moreover, its
conceptual equivalence and cultural adaptability across countries
were considered early in the development process. To date, the
OAB-S is available in ﬁve languages including US-English, US-
Spanish, UK-English, Spain-Spanish and German. METHODS:
The cultural and linguistic equivalence of the OAB-S was ensured
at different stages of the development and the translation
processes: 1) the OAB-S was simultaneously developed in US-
English and US-Spanish and tested for face and content validity;
2) the pre-ﬁnal original questionnaire underwent a translatabil-
ity assessment, an international critical review with the objective
of suggesting re-formulations in the pre-ﬁnal version considering
the context and constraints of other languages and cultures; 3)
ﬁnally, the OAB-S was translated into the three remaining lan-
